Literature DB >> 20684863

RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo.

Yangchao Chen1, Dan Xie, Wing Yin Li, Chi Man Cheung, Hong Yao, Ching Yu Chan, Chu-yan Chan, Fang-Ping Xu, Yan-Hui Liu, Joseph J Y Sung, Hsiang-fu Kung.   

Abstract

The function of EZH2 in tumorigenesis and liver metastasis of pancreatic cancer has never been elucidated in vivo. EZH2 was overexpressed in pancreatic carcinomas and its overexpression was associated with tumor differentiation and pT status. Suppression of EZH2 caused a significant growth inhibition of pancreatic cancer cells in vitro and markedly diminished their tumorigenicity in vivo. Knock-down of EZH2 inhibited liver metastasis of pancreatic cancer in vivo. EZH2 has a crucial role in tumor growth and liver metastasis of pancreatic cancer. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20684863     DOI： 10.1016/j.canlet.2010.05.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  23 in total

1.  MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer.

Authors:  Liming Xie; Zhiwei Zhang; Zhiqin Tan; Rongfang He; Xi Zeng; Yuanjie Xie; Suyun Li; Guohua Tang; Hailin Tang; Xiusheng He
Journal:  Mol Cell Biochem       Date:  2014-07       Impact factor: 3.396

Review 2.  Polycomb and the emerging epigenetics of pancreatic cancer.

Authors:  Adrienne Grzenda; Tamas Ordog; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 3.  Targeting CSC-related miRNAs for cancer therapy by natural agents.

Authors:  Bin Bao; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Ginny Bao; Shadan Ali; Sanjeev Banerjee; Dejuan Kong; Fazlul H Sarkar
Journal:  Curr Drug Targets       Date:  2012-12       Impact factor: 3.465

4.  Histone modifiers in cancer: friends or foes?

Authors:  Idan Cohen; Elżbieta Poręba; Kinga Kamieniarz; Robert Schneider
Journal:  Genes Cancer       Date:  2011-06

5.  Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

Authors:  Amir Avan; Francesco Crea; Elisa Paolicchi; Niccola Funel; Elena Galvani; Victor E Marquez; Richard J Honeywell; Romano Danesi; Godefridus J Peters; Elisa Giovannetti
Journal:  Mol Cancer Ther       Date:  2012-05-23       Impact factor: 6.261

6.  Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.

Authors:  Bin Bao; Shadan Ali; Sanjeev Banerjee; Zhiwei Wang; Farah Logna; Asfar S Azmi; Dejuan Kong; Aamir Ahmad; Yiwei Li; Subhash Padhye; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2011-11-22       Impact factor: 12.701

7.  CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.

Authors:  Xin Jin; Chong Yang; Ping Fan; Jun Xiao; Wanli Zhang; Sudong Zhan; Tao Liu; Dejie Wang; Heshui Wu
Journal:  J Biol Chem       Date:  2017-02-27       Impact factor: 5.157

Review 8.  Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Feras Zaiem; Fazlul H Sarkar
Journal:  Ann Transl Med       Date:  2014-06

9.  Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors.

Authors:  Mao-Rong Zhu; Dao-Hai Du; Jun-Chi Hu; Lian-Chun Li; Jing-Qiu Liu; Hong Ding; Xiang-Qian Kong; Hua-Liang Jiang; Kai-Xian Chen; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

10.  EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.

Authors:  Lilian E van Vlerken; Christine M Kiefer; Chris Morehouse; Ying Li; Chris Groves; Susan D Wilson; Yihong Yao; Robert E Hollingsworth; Elaine M Hurt
Journal:  Stem Cells Transl Med       Date:  2012-12-27       Impact factor: 6.940
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.